AbbVie (ABBV) News Today

AbbVie Inc. (NYSE:ABBV) shares are trading near record highs as investors digest a series of positive analyst actions, clinical updates and market reports. Key developments include:

• Positive Sentiment: AbbVie reported encouraging data from its two-part clinical study of GUB014295, a potential weight-management therapy that could broaden its pipeline. AbbVie’s Promising Study on GUB014295
• Positive Sentiment: Zacks Research raised its Q2 2027 EPS forecast for ABBV to $3.85 (from $3.84) and lifted its FY2027 estimate to $15.25 (from $15.20), signaling a stronger earnings outlook. Zacks Research Issues Optimistic Outlook
• Positive Sentiment: MarketBeat reports ABBV holds an average “Moderate Buy” rating from 27 analysts, with 17 recommending buy versus 6 holding. AbbVie Receives “Moderate Buy” Rating
• Positive Sentiment: AbbVie shares rose about 1.8% following an analyst upgrade, reflecting growing investor confidence. Trading Up 1.8% After Upgrade
• Positive Sentiment: Berenberg Bank upgraded ABBV to a Buy rating, adding to recent bullish analyst actions. Raised to Buy at Berenberg Bank
• Positive Sentiment: ABBV stock hit an all-time high of $221.80, underscoring continued upward momentum. Stock Hits All-Time High
• Positive Sentiment: BMO Capital Markets boosted ABBV’s price target to $240 after a favorable Rinvoq litigation win, highlighting reduced legal risk. BMO Lifts Price Target to $240
• Positive Sentiment: Shares set a new 52-week high following another round of analyst upgrades. Sets New 12-Month High
• Positive Sentiment: Berenberg also lifted its outlook on ABBV while downgrading peers Lilly and Merck, a relative win for AbbVie. Berenberg Boost for ABBV
• Positive Sentiment: AbbVie reached settlements with generic manufacturers over its Rinvoq arthritis drug, removing a key legal overhang. Rinvoq Settlement
• Positive Sentiment: JPMorgan analysts forecast strong price appreciation for ABBV, citing robust fundamentals and pipeline strength. JPMorgan Forecasts Strong Appreciation
• Neutral Sentiment: The Motley Fool lists ABBV among three “unstoppable” dividend stocks to consider in a market sell-off, noting its reliable payout. 3 Unstoppable Dividend Stocks
• Neutral Sentiment: An industry report on acute bacterial skin-structure infections highlights AbbVie as a key player in the ABSSSI treatment market. ABSSSI Market Insights